About Drug Delivery to the Lungs (DDL)
Drug Delivery to the Lungs (DDL), now marking its 36th edition, is one of the leading gatherings in the respiratory drug delivery field. It draws over 1,100 attendees worldwide, including scientists, clinicians, academics, regulators, and industry professionals. The conference features lectures, an industry exhibition, a scientific poster hall, and networking opportunities.
DDL 2025 – Dates, Venue & Location
Date: 10–12 December 2025
Venue: Edinburgh International Conference Centre (EICC), The Exchange, Edinburgh, Scotland, UK
Meet with Upperton Pharma Solutions
We are experts in oral solids, nasal and pulmonary dosage forms, able to support you to Phase I quickly or help you transition into Phase II and scale up to Phase III.
From pre-clinical to market, all in one place
Our flexibility and science-led approach saves time, reduces risk and provides pathways from
early-phase clinical studies to commercialisation with confidence.
One team, from start to finish
We keep the knowledge of your molecule within the same project team, ensuring continuity and access to subject matter expertise across all layers of our business.
One site, to accelerate through phases
We accelerate your molecule through clinical phases without transfer delays, with one integrated facility across R&D, GMP and QC, located in Nottingham, UK.
One destination, with a trusted track record
Our regulatory record ensures you’re in good hands to progress your drug development pipeline with quality, speed and confidence.
Discover more about our integrated CDMO services and expertise in oral, nasal and pulmonary dosage forms.
Meet our team of experts
Ian Lafferty
Chief Technical Officer
Richard Johnson
Chief Scientific Officer & Founder
Michael Mellor-Clark
Chief Commercial Officer
Myles Terrey
Business Development Manager
Request a meeting
Connect with our experts and request a meeting to learn more about our integrated CDMO services.